Recent Updates
Recently added Catalysts
AZN Positive Sentiment

Susan G. Komen® and AstraZeneca Partnership to Make Patient Navigation Available to All

Monday, September 14, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Susan G. Komen has partnered with AstraZeneca to enhance patient navigation in breast cancer care. This initiative aims to integrate patient navigation into the national healthcare system, addressing barriers and improving access to timely treatments. The collaboration seeks to reduce patient stress and enhance adherence to cancer care plans across the nation.

Market Sentiment Analysis

POSITIVE FACTORS

  • Partnership aims to improve patient navigation for breast cancer.
  • Focus on reducing barriers and improving treatment access.
  • Collaboration will enhance adherence to cancer care plans.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+10%
120-day peak, hindsight
Typical move
1.4%
average across 15 past catalysts
Lead asset
Elecoglipron
Phase 3 · Heart Failure With Preserved Ejection Fraction (HFpEF)

Full Press Release Details

DALLAS--(BUSINESS WIRE)--Susan G. Komen®, the world’s leading breast cancer organization, has announced a partnership with AstraZeneca to make patient navigation part of the national health care infrastructure to help patients overcome barriers, access timely treatment, reduce stress and improve adherence to cancer care plans. Komen and AstraZeneca will build a Navigation Infrastructure Collaboration to strengthen patient navigation nationwide by developing the evidence, infrastructure and scala

Frequently Asked Questions

What is the goal of the Komen and AstraZeneca partnership?

The partnership aims to enhance patient navigation in breast cancer care.

How will the partnership improve patient care?

It will address barriers, improve access to treatment, and enhance adherence.

What is patient navigation?

Patient navigation helps individuals overcome obstacles to receive timely cancer care.

Who is involved in this partnership?

The partnership involves Susan G. Komen and AstraZeneca.

ShareAdd on Google
Tags: AZN Viatris Investor Conferences Healthcare AstraZeneca Susan G. Komen breast cancer patient navigation cancer care
Last updated: Sep 14, 2026

Biotech snapshot

Lead asset
ElecoglipronPhase 3
Heart Failure With Preserved Ejection Fraction (HFpEF) →

Catalyst track record

+10%
best trade around AZN's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for AZN.

See every catalyst's timing & PoA →